Bumper Offer - Urjas oil Just @ Rs. 1
Arbitel R 40/2.5 Tablet is a prescription medicine that is available as a Tablet. Other than this, Arbitel R 40/2.5 Tablet has some other therapeutic uses, which have been discussed ahead.
Medical history of the patient along with age and gender determines the dosage of Arbitel R 40/2.5 Tablet. The condition it has been prescribed for, and the route of administration also determine the right dosage. Detailed information has been provided in the dosage section.
Arbitel R 40/2.5 Tablet also has some side effects, the most common being Dizziness, Nausea or vomiting, Back Pain. Apart from the aforementioned side effects, Arbitel R 40/2.5 Tablet can also lead to other problems, which have been listed below. Such side effects of Arbitel R 40/2.5 Tablet normally do not last long and go away once the treatment is completed. Consult your doctor if these side effects become worse or stay for a longer duration.
Furthermore, you should know that effect of Arbitel R 40/2.5 Tablet is Severe for pregnant women and Mild for women who are breastfeeding. Warnings related to Arbitel R 40/2.5 Tablet's effects on the liver, heart and kidney, if any, have been listed below.
Arbitel R 40/2.5 Tablet can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Arbitel R 40/2.5 Tablet in conditions like Angioedema, Hyperkalemia, Drug Allergy. The section on Arbitel R 40/2.5 Tablet contraindications lists all such conditions.
Additionally, Arbitel R 40/2.5 Tablet may also adversely react with other medicines. Refer to the list below for further details.
Along with the above-mentioned precautions, remember that taking Arbitel R 40/2.5 Tablet is considered not safe while driving, and is not addictive.
Arbitel R 40/2.5 Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
Based on research, the following side effects have been observed when Arbitel R 40/2.5 Tablet is used -
Severe
Mild
Common
Is the use of Arbitel R 40/2.5 Tablet safe for pregnant women?
Arbitel-R should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Arbitel R 40/2.5 Tablet safe during breastfeeding?
Breastfeeding women can take Arbitel-R as it bears very minor side effects for them.
What is the effect of Arbitel R 40/2.5 Tablet on the Kidneys?
Arbitel-R rarely harms the kidneys.
What is the effect of Arbitel R 40/2.5 Tablet on the Liver?
Arbitel-R has very mild side effects on the liver.
What is the effect of Arbitel R 40/2.5 Tablet on the Heart?
Side effects of Arbitel-R rarely affect the heart.
Arbitel R 40/2.5 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Arbitel R 40/2.5 Tablet unless your doctor advises you to do so -
Is this Arbitel R 40/2.5 Tablet habit forming or addictive?
No, there is no any evidence that Arbitel R 40/2.5 Tablet is addictive.
Interaction between Food and Arbitel R 40/2.5 Tablet
Taking Arbitel R 40/2.5 Tablet with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Arbitel R 40/2.5 Tablet
It is difficult to say anything about the effect of Arbitel R 40/2.5 Tablet and alcohol. No research has been done on this yet.
Yes, it is safe to take Arbitel-R as long as it is prescribed by your doctor. However, in some people, it may cause some side effects like back pain, sinusitis, and diaarhea.
Arbitel-R contains telmisartan which is an antihypertensive drug that works by preventing a chemical (angiotensin II) to bind with a receptor. This causes relaxation of blood vessels, it also prevents the synthesis and release of aldosterone (a hormone whose hyperactivity results in high blood pressure). In this way Arbitel-R decreases the blood pressure.
Arbitel-R is the brand name for telmisartan. It belongs to a group of medications known as angiotensin II receptor blockers. It is available in the form of tablets. Arbitel-R is used to treat hypertension. It is also used to decrease cardiovascular risk in patients who cannot take ACE (angiotensin-converting enzyme) inhibitors.
No, Arbitel-R is not bad for kidneys. In fact, it protects the kidneys, thus, it is suitable for people with diabetes and mild-to-moderate kidney disease.
Arbitel-R is available in the form of tablets. A tablet is usually taken once a day, with or without food because food affects the absorption of this drug. It should be taken at exactly the same time every time to avoid skipping the dose. Arbitel-R might start showing the effects between 2 to 4 weeks, therefore, it is important to continue taking it even when you feel well. One should take Arbitel-R exactly as prescribed by their doctor.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 169-173
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 507
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Micardis® (telmisartan)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Twynsta® (telmisartan/amlodipine)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Altace (ramipril)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 163-169
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 503